Navigation Links
EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
Date:5/29/2013

A further report on the results of EORTC trial 26951 indicates that CpG island methylator phenotype (CIMP) status and O 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation as assessed by MGMT-STP27 are the most informative for identifying grade III glioma patients who might benefit from the addition of procarbazine, CCNU and vincristine (PCV) chemotherapy to radiation therapy. Prior results had shown that PCV chemotherapy following standard radiation therapy delayed tumor growth and extended the lives of patients with anaplastic oligodendroglial tumors, a hard-to-treat form of brain cancer.

Results observed in the phase III RTOG 9402 trial, in this case with chemotherapy preceding radiation therapy, complemented the results obtained previously in the EORTC 26951 trial and found that administering both PCV and radiation therapy led to comparable improvements in survival for oligodendroglial tumor patients with specific deletions of genetic material in chromosomes 1p and 19q, but not for patients without the mutation.

Nevertheless up to 30% of oligodendroglial tumors do not have 1p/19q deletion but may still respond to chemotherapy. Analyses of EORTC 26951 and RTOG 9402 suggested that other molecularly defined subsets of grade III tumors might benefit as well.

The new results will be presented at an ASCO 2013 Clinical Science Symposia on Sunday, 02 June 2013 by Dr. Martin J. Van Den Bent of the Erasmus Medical Centre Cancer Institute, Rotterdam, The Netherlands, and coordinator of the study. According to Dr. Van Den Bent, "This is further evidence pointing towards a central role of methylation in the behavior of IDH (isocitrate dehydrogenase) mutated glioma and, more in general, of the MGMT gene function in glioma when treated with chemotherapy."

Methylation profiles of 115 patients were conducted using Infinium HumanMethylation27 or Infinium HumanMethylation450 BeadChip kits. (Validation in an independent dataset is required.)

In these analyses, two markers, CIMP and MGMT-STP27 methylation status, were considered promising in being able to differentiate between patients who will and will not respond to PCV chemotherapy. Two other markers, IDH mutation status and 1p/19 chromosomal deletion, had less strength in achieving this differentiation.

The EORTC 26951 intergroup trial was coordinated by the EORTC Brain Tumor Group in collaboration with the Medical Research Council Clinical Trial Unit and supported by Stichting STOPhersentumor.nl. This academic trial was activated in August 1996, closed in March 2002, and included 368 patients in 40 sites in 10 countries: Austria, Belgium, Finland, France, Germany, Hungary, Italy, Sweden, The Netherlands, and the United Kingdom.


'/>"/>

Contact: John Bean
john.bean@eortc.be
32-277-41671
European Organisation for Research and Treatment of Cancer
Source:Eurekalert

Related medicine news :

1. EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
2. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
3. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Now Offer New Guided Weight Loss Tips Now Found in New Study to Help Patients Lose Weight Fast
4. A Strong Marriage Can Shield Kids From Dads Depression: Study
5. Narconon Releases Early Study of Delaware Prison Program, Demonstrating Crime Reduction Consistent with More Recent Narconon Results
6. Changing gut bacteria through diet affects brain function, UCLA study shows
7. GOJO presents electronic hand hygiene compliance study at APIC conference
8. Alzheimers Patients Mimic Emotions of Those Around Them: Study
9. Study: Ipilimumab Shows Durable Responses But Low Overall Response Rate In Patients With Unresectable Or Metastatic Mucosal Melanoma
10. Kids Poisoned by Medical Marijuana, Study Finds
11. Involving Patients in Decisions Raises Health Care Costs, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: